Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 15Kidney Neoplasms 3Urologic Neoplasms 1Urinary Bladder Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Clear-cell metastatic renal cell carcinoma 1Adrenal Gland Neoplasms 1

Interventions

Nivolumab 14Ipilimumab 11Specimen Handling 9CTLA-4 Antigen 7pembrolizumab 6cabozantinib 6Magnetic Resonance Spectroscopy 6Sunitinib 5Axitinib 5pazopanib 4Biopsy 4Radiosurgery 3lenvatinib 2fludarabine 2Everolimus 2tivozanib 1sodium-iodide symporter 1sitravatinib 1belzutifan 1atezolizumab 1aldesleukin 1Zoledronic Acid 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Pluvicto 1Nephrectomy 1Metastasectomy 1LY2510924 1Inulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Clear-cell metastatic renal cell carcinoma × Nephrectomy × Clear all
NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

University of California, San Francisco

Phase 2 Terminated
6 enrolled 11 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡